Moreover, we demonstrate the efficiency of the pan-PIM inhibitor PIM447 against those cells that rely on JAK/STAT pathway mutations recurrently identified in T-ALL/LBL for their growth and viability. This evidence concerns the gene PIM1 and acute lymphoblastic leukemia.